新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 糖尿病药物市场 » CHMP建议批准强生糖尿病新药VOKANAMET

CHMP建议批准强生糖尿病新药VOKANAMET

来源:生物谷 2014-02-23 05:03

2014年2月22日讯 /生物谷BIOON/ --强生(JNJ)旗下杨森(Janssen)2月21日宣布,糖尿病新药VOKANAMET获得了欧洲药品管理局(EMA)人用医药产品委员会(CHMP)的积极意见。CHMP建议批准VOKANAMET用于2型糖尿病患者的治疗。

VOKANAMET是由固定剂量canagliflozin和速释二甲双胍(metformin)组成的单一片剂。

Canagliflozin(商品名INVOKANA)是日服一次的口服糖尿病药物,已分别于2013年3月和11月获FDA和欧盟批准上市,该药属于选择性纳葡萄糖共转运体2(SGLT2)抑制剂的一类新药,通过阻断肾脏对血糖的重吸收及增加尿液中血糖的排泄,来降低机体血糖水平。

与非糖尿病人群相比,2型糖尿病患者的肾脏能够重吸收大量的葡萄糖进入血液,这可能会推高血糖水平。

二甲双胍则是2型糖尿病治疗的一线药物,可单独或与其他药物(包括胰岛素)联合用药。在2型糖尿病患者中,肝脏产生过量的葡萄糖(glucose),从而提高血糖水平。二甲双胍可通过降低肝脏产生葡萄糖的量、增加肌肉对葡萄糖的敏感性、延缓肠道的葡萄糖吸收,降低机体的血糖水平。(生物谷Bioon.com)

英文原文:VOKANAMET? (canagliflozin and metformin fixed dose combination) receives positive CHMP opinion recommending approval in the European Union for the treatment of adults with type 2 diabetes[1]

BEERSE, February 21 2014 - Janssen-Cilag International NV (Janssen) announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorisation in the European Union for the medicinal product VOKANAMET?, a fixed-dose therapy combining canagliflozin and immediate release metformin in a single tablet, intended for the treatment of type 2 diabetes mellitus.[1] Canagliflozin is currently available as INVOKANA? following approval in the European Union in November 2013.

Professor Guntram Schernthaner, Department of Medicine I, Rudolfstiftung Hospital, Austria, comments "If approved, VOKANAMET? will offer an additional treatment option in the management of type 2 diabetes in Europe. Metformin as a first line therapy for type 2 diabetes has offered real hope for patients to achieve their treatment goals. The potential of combining canagliflozin's mode of action with metformin provides an exciting approach to diabetes management, offering patients the benefits of blood glucose and body weight reduction without increasing the risk for hypoglycaemia."

Canagliflozin is approved in the European Union for the treatment of adult patients with type 2 diabetes mellitus, to improve glycaemic control.[2] It is a member of a new class of drugs known as sodium glucose co-transporter 2 (SGLT2) inhibitors. It plays an important role in the kidney and contributes to controlling blood glucose levels. As glucose is filtered from the blood into the kidneys, it is reabsorbed back into the bloodstream. An important carrier responsible for this reabsorption is called sodium glucose co-transporter 2 (SGLT2). Canagliflozin selectively inhibits SGLT2, and, as a result, promotes the loss of glucose via the urine, lowering blood glucose levels in adults with type 2 diabetes.

Metformin is a first-line pharmacotherapy that can be used alone or with other medications, including insulin, to treat type 2 diabetes. In people with type 2 diabetes, the liver overproduces glucose, which increases blood glucose levels. Metformin lowers blood glucose levels by decreasing the amount of glucose made by the liver, increasing insulin sensitivity in the muscle and delaying intestinal glucose absorption. [3]

If approved, this canagliflozin and metformin fixed dose combination therapy could provide a new treatment option for the management of adults with type 2 diabetes mellitus and convenience for patients who may benefit from two diabetes medications in one tablet.

Significant portions of the clinical data in this Marketing Authorisation Application (MAA) are derived from the comprehensive global Phase 3 clinical development programme for canagliflozin single agent.

The Phase 3 programme evaluated the safety and efficacy of canagliflozin across the spectrum of type 2 diabetes and included placebo and active comparator controlled studies. Three studies have compared canagliflozin to current standard treatments[4-6], two of which compared canagliflozin to sitagliptin as triple therapy with metformin and sulphonylurea[4,5] and the other to glimepiride as dual therapy with metformin.[6] The Phase 3 programme also included two large studies in special populations[7-9]: patients over 55 with type 2 diabetes[7] and patients with type 2 diabetes who were considered to be at high risk for cardiovascular disease.[9]

Single agent canagliflozin (INVOKANA?) was approved in the US in March 2013, throughout all 28 member countries of the European Union in November 2013 and in a growing number of countries around the world.

The CHMP is the committee responsible for the scientific assessment of products seeking centralised marketing authorisation throughout the European Union. The CHMP's positive opinion recommending the approval of the fixed dose combination of canagliflozin and metformin is now referred to the European Commission. Janssen anticipates receiving the regulatory decision from the European Commission in the coming months.

Janssen and its affiliates have rights to canagliflozin through a license agreement with Mitsubishi Tanabe Pharma Corporation. Janssen and its affiliates have marketing rights in North America, South America, Europe, the Middle East, Africa, Australia, New Zealand and parts of Asia.

About Type 2 Diabetes
Type 2 diabetes is a chronic condition that affects the body's ability to metabolise sugar, or glucose, and is characterised by the inability of pancreatic beta cell function to keep up with the body's demand for insulin.[10]

The International Diabetes Federation estimates that, in 2013, 382 million people globally were living with diabetes (type 1 and 2) in 2013, and the diabetes population is expected to grow to over 592 million by 2035.[11] The World Health Organisation estimates that 90% of the diabetes population have type 2 diabetes.[12]

If left uncontrolled, type 2 diabetes can lead to serious long-term microvascular and macrovascular complications. Improved glycemic control has been demonstrated to reduce the onset and progression of these complications.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库